The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production.
In our recent study we described a significant antileukemic efficacy of a combination therapy with interleukin-12 (IL-12) and doxorubicin (DOX) in the L1210 leukemia model. This therapeutic effect was abrogated by elimination of activated macrophages. Activated macrophages produce a variety of factors that can contribute to the elimination of tumor cells in vivo, including proteases, TNF, reactive oxygen intermediates, and nitric oxide (NO). Based on the results of previous reports, the contribution of NO in potentiated antileukemic effects of IL-12 + DOX combination seemed to be highly possible. Both DOX and IL-12 given alone increased the production of NO by peritoneal macrophages, however, macrophages derived from the mice treated with the combination of those agents produced significantly less NO than macrophages from IL-12-alone-treated mice. Production of NO by spleen macrophages after IL-12 + DOX treatment was higher than it was in controls, IL-12-alone or DOX-alone-treated groups. In serum, concentrations of NOx- in IL-12- or IL-12 + DOX-treated mice were significantly higher in comparison with controls, however not significantly different from each other. Addition of L-NAME treatment to the IL-12 + DOX therapy in leukemia-bearing mice did not significantly change the antileukemic efficacy of this therapy. Thus, our results indicate that the augmented antileukemic effects of IL-12 + DOX combination therapy in L1210 model are NO-independent. Therefore, further studies on the possible mechanisms of potentiated antileukemic activity of combination of IL-12 and DOX would be worth pursuing.
Zagozdzon
R
R
Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Poland. rzagozd@ib.amwaw.edu.pl
Giermasz
A
A
Gołab
J
J
Stokłosa
T
T
Jalili
A
A
Jakóbisiak
M
M
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002478:Cells, Cultured; D003433:Crosses, Genetic; D004317:Doxorubicin / Q000008:administration & dosage; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D018664:Interleukin-12 / Q000008:administration & dosage; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009368:Neoplasm Transplantation; D009566:Nitrates / Q000097:blood; D009569:Nitric Oxide / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D009573:Nitrites / Q000097:blood; D013154:Spleen / Q000187:drug effects / Q000378:metabolism; D015996:Survival Rate
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D004791:Enzyme Inhibitors; D009566:Nitrates; D009573:Nitrites; D018664:Interleukin-12; D009569:Nitric Oxide; D004317:Doxorubicin; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester